Entero Therapeutics (FRA:366) 5-Year EBITDA Growth Rate : 72.10% (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Entero Therapeutics 5-Year EBITDA Growth Rate?

Entero Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €-0.58.

During the past 3 years, the average EBITDA Per Share Growth Rate was 87.90% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 72.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 10 years, the highest 3-Year average EBITDA Per Share Growth Rate of Entero Therapeutics was 87.90% per year. The lowest was 12.70% per year. And the median was 41.50% per year.

Competitive Comparison of Entero Therapeutics's 5-Year EBITDA Growth Rate

For the Biotechnology subindustry, Entero Therapeutics's 5-Year EBITDA Growth Rate, along with its competitors' market caps and 5-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Entero Therapeutics's 5-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entero Therapeutics's 5-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Entero Therapeutics's 5-Year EBITDA Growth Rate falls into.

Entero Therapeutics 5-Year EBITDA Growth Rate Calculation

This is the 5-year average growth rate of EBITDA per Share. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Entero Therapeutics (FRA:366) 5-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

5-Year EBITDA Growth Rate gives an overview of the company's growth in operating profitability and is an important factor used in calculating Peter Lynch Fair Value.

Entero Therapeutics 5-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Entero Therapeutics's 5-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Entero Therapeutics (FRA:366) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entero Therapeutics Inc (FRA:366) » Definitions » 5-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ENTO:USA

Address

777 Yamato Road, Suite 502, Boca Raton, FL, USA, 33431

Website

https://www.firstwavebio.com

First Wave BioPharma Inc is a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal diseases. It is advancing a therapeutic development pipeline populated with multiple clinical-stage programs built around its two proprietary technologies-niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties, and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients.

Entero Therapeutics (FRA:366) Headlines

No Headlines